Jefferies raised the firm’s price target on Labcorp (LH) to $300 from $290 and keeps a Buy rating on the shares. The company delivered a solid beat and raise quarter, with the Bioanalytical Lab Solutions & Services beat and backlog an encouraging sign for its Endocrine Disruptor moving forward, the analyst tells investors in a research note. The firm added that while the guidance raise was driven by foreign exchange, it continues to like the setup.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp price target raised to $300 from $285 at Evercore ISI
- Early notable gainers among liquid option names on July 24th
- Labcorp Holdings: Strong Performance, Strategic Growth, and Valuation Advantage Support Buy Rating
- Morning Movers: Dow Inc. falls following Q2 report and dividend cut
- Labcorp Holdings: Strategic Acquisitions and Growth Initiatives Drive Buy Rating